Objectives SARS-CoV2 infection leads to a concomitant pulmonary inflammation. This
inflammation is supposed to be the main driver in the pathogenesis of lung failure (Acute …

Introduction Tocilizumab randomized clinical trial results are heterogeneous because of the
heterogenous population included in them. Methods We conducted a meta-analysis with …

Background Pneumonia with severe respiratory failure represents the principal cause of
death in COVID-19, where hyper-inflammation plays an important role in lung damage. An …

Background In COVACTA, a randomised, placebo-controlled trial in patients hospitalised
with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but …

In this article, we express our opinion about tocilizumab as an effective treatment in
coronavirus disease 2019, based on a narrative review and a deep analysis of tocilizumab …

Objectives Currently published papers and clinical guidelines regarding the effects of
tocilizumab in severe and critical COVID-19 are contradictory. The aim of this meta-analysis …

Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …

Background To date, only dexamethasone has been shown to reduce mortality in
coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the …

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be
beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted …

Tocilizumab is an interleukin receptor inhibitor that has been used in patients with COVID-19
pneumonia. There are recent randomized controlled trials (RCTs) that evaluated the efficacy …